{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:29:36Z","timestamp":1782451776863,"version":"3.54.5"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01948","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T12:26:44Z","timestamp":1565785604000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies"],"prefix":"10.3389","volume":"10","author":[{"given":"Maria-Grazia","family":"Lazzaroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Fredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia Beatrice","family":"Chighizola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Del Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gerosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kuzenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Gabriella","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lojacono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ramazzotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Zatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Trespidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier-Luigi","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Pengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Ruffatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Tincani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (aps)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.autrev.2015.01.002","article-title":"The relevance of \u201cnon-criteria\u201d clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features","volume":"14","author":"Abreu","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41584-018-0032-6","article-title":"Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?","volume":"14","author":"Meroni","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1136\/ard.2008.096669","article-title":"Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study","volume":"68","author":"Ruffatti","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/art.33341","article-title":"Beyond the \u201csyndrome\u201d: Antiphospholipid antibodies as risk factors","volume":"64","author":"Andreoli","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1093\/rheumatology\/ker139","article-title":"Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case\u2013control study","volume":"50","author":"Ruffatti","year":"2011","journal-title":"Rheumatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.3109\/14767058.2016.1152254","article-title":"Maternal and fetal outcome in women with antiphospholipid syndrome: a three-year observational study","volume":"29","author":"Rezk","year":"2016","journal-title":"J Matern Fetal Neonatal Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.autrev.2014.02.003","article-title":"14th international congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome","volume":"13","author":"De Jesus","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3389\/fimmu.2018.00864","article-title":"Risk factors for adverse maternal and fetal outcomes in women with confirmed apl positivity: results from a multicenter study of 283 pregnancies","volume":"9","author":"Fredi","year":"2018","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0961203317692432","article-title":"Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile","volume":"26","author":"Latino","year":"2017","journal-title":"Lupus"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B14","doi-asserted-by":"publisher","first-page":"525. e1","DOI":"10.1016\/j.ajog.2017.01.026","article-title":"Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the pregnants study","volume":"216","author":"Saccone","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.autrev.2014.12.010","article-title":"The european registry on obstetric antiphospholipid syndrome (euroaps): a survey of 247 consecutive cases","volume":"14","author":"Alijotas-Reig","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"CD002859","DOI":"10.1002\/14651858.CD002859.pub2","article-title":"Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant","volume":"18","author":"Empson","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"Eular recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1177\/0961203315578765","article-title":"Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review","volume":"24","author":"Amengual","year":"2015","journal-title":"Lupus"},{"key":"B20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3899\/jrheum.120576","article-title":"Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study","volume":"40","author":"Del Ross","year":"2013","journal-title":"J Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1538-7836.2010.03747.x","article-title":"Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies","volume":"8","author":"Chauleur","year":"2010","journal-title":"J Thromb Haemost"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.02.003","article-title":"The treatment of anti-phospholipid syndrome: a comprehensive clinical approach","volume":"90","author":"Chighizola","year":"2018","journal-title":"J Autoimmun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1055\/s-0038-1649901","article-title":"Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on lupus anticoagulant\/antiphospholipid antibody of the scientific and standardisation committee of the isth","volume":"74","author":"Brandt","year":"1995","journal-title":"Thromb Haemost"},{"key":"B24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.autrev.2014.05.001","article-title":"14th international congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends","volume":"13","author":"Bertolaccini","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.thromres.2004.06.035","article-title":"Minimal requirements for antiphospholipid antibodies elisas proposed by the european forum on antiphospholipid antibodies","volume":"114","author":"Tincani","year":"2004","journal-title":"Thromb Res"},{"key":"B26","first-page":"1742","article-title":"A \u201cprimary\u201d antiphospholipid syndrome?","volume":"15","author":"Asherson","year":"1988","journal-title":"J Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e000131","DOI":"10.1136\/lupus-2015-000131","article-title":"Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in apl-positive patients: validation of PROMISSE study results","volume":"3","author":"Yelnik","year":"2016","journal-title":"Lupus Sci Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.thromres.2018.03.008","article-title":"Clinical and laboratory characteristics of isolated lupus anticoagulants","volume":"165","author":"Mattia","year":"2018","journal-title":"Thromb Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.thromres.2018.11.003","article-title":"Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns","volume":"172","author":"Pengo","year":"2018","journal-title":"Thromb Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaut.2018.02.002","article-title":"Beyond thrombosis: anti-\u03b22gpi domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome","volume":"90","author":"Chighizola","year":"2018","journal-title":"J Autoimmun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3899\/jrheum.170751","article-title":"Antiphosphatidylserine\/prothrombin antibodies in antiphospholipid syndrome with intrauterine growth restriction and preeclampsia","volume":"45","author":"Canti","year":"2018","journal-title":"J Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/rheumatology\/ket173","article-title":"Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes","volume":"52","author":"Soh","year":"2013","journal-title":"Rheumatology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.medcle.2017.11.052","article-title":"Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies","volume":"151","author":"Alijotas-Reig","year":"2018","journal-title":"Med Clin."},{"key":"B34","first-page":"551","article-title":"Adjusted prophylactic doses of nadroparin plus low dose aspirin therapy in obstetric antiphospholipid syndrome. A prospective cohort management study","volume":"29","author":"Ruffatti","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1160\/th15-06-0491","article-title":"The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment","volume":"115","author":"Sciascia","year":"2016","journal-title":"Thromb Haemost"},{"key":"B36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/aji.12184","article-title":"Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function","volume":"71","author":"Albert","year":"2014","journal-title":"Am J Reprod Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a european multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1055\/s-0038-1632388","article-title":"Effect of additional treatments combined with conventional therapies in pregnant patients with high-risk antiphospholipid syndrome: a multicentre study","volume":"118","author":"Ruffatti","year":"2018","journal-title":"Thromb Haemost"},{"key":"B39","doi-asserted-by":"publisher","first-page":"273.e1","DOI":"10.1016\/j.ajog.2015.09.078","article-title":"The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies","volume":"214","author":"Sciascia","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.autrev.2017.05.006","article-title":"Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a european multicenter retrospective study","volume":"16","author":"Mekinian","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1055\/s-0037-1603359","article-title":"Hydroxychloroquine to improve pregnancy outcome in women with antiphospholipid antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies","volume":"43","author":"Schreiber","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"B42","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.gofs.2018.06.008","article-title":"Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: french phase ii multicenter randomized trial, HYDROSAPL","volume":"46","author":"Mekinian","year":"2018","journal-title":"Gynecol Obstet Fertil Senol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1177\/0961203318787032","article-title":"Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome","volume":"27","author":"Yelnik","year":"2018","journal-title":"Lupus"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3899\/jrheum.161364","article-title":"Longterm outcome of patients with primary antiphospholipid syndrome: a retrospective multicenter study","volume":"44","author":"Taraborelli","year":"2017","journal-title":"J Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/1471-0528.15469","article-title":"Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (aps) in the aps alliance for clinical trials and international networking clinical database and repository: a retrospective study","volume":"126","author":"de","year":"2019","journal-title":"BJOG"},{"key":"B46","first-page":"OC1.2","article-title":"Relationship between tsh values in the first trimester of pregnancy and obstetric and neonatal complications. ECE 2018","volume-title":"Proceedings of the 20th European Congress of Endocrinology","author":"Moreno","year":"2018"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3389\/fimmu.2018.01388","article-title":"Pathogenic role of complement in anti-phospholipid syndrome and therapeutic implications","volume":"9","author":"Tedesco","year":"2018","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/rheumatology\/kes225","article-title":"Primary anti-phospholipid syndrome: Any role for serum complement levels in predicting pregnancy complications?","volume":"51","author":"Reggia","year":"2012","journal-title":"Rheumatology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/annrheumdis-2017-212224","article-title":"Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and\/or antiphospholipid antibodies","volume":"77","author":"Kim","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.7326\/M14-2235","article-title":"Predictors of pregnancy outcomes in patients with lupus: a cohort study","volume":"163","author":"Buyon","year":"2015","journal-title":"Ann Intern Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01948\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T12:26:46Z","timestamp":1565785606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01948\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2019.01948"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01948","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"article-number":"1948"}}